



Immuron is Now US OTCQB Listed

10 September 2015, Melbourne, Australia: Immuron Limited (ASX:IMC) is pleased to announce that further to the announcement on 1st Sept 2015 advising the Company had applied for an US OTCQB Listing, Immuron is now US OTCQB listed.

Following confirmation of the US listing Immuron CEO Mr. Thomas Liquard said:

"We are excited about our up-listing to the US OTCQB as it demonstrates Immuron's commitment to increasing liquidity for our shareholders and the advancement of our efforts to fully access the US capital markets which we believe is critical to drive long-term shareholder value."

OTCQB is an Over-The-Counter (OTC) decentralised market where securities not listed on a major US exchange can be traded directly and electronically by market participants through an Established Public Markets platform which is recognised by the US Securities & Exchange Commission (SEC).

The OTCQB listing will provide Immuron with a direct link to a diverse network of brokers and dealers who can provide liquidity and execution services for the Company's securities in the US.

The Board is confident that the increased US exposure will allow a more complete assessment of the Company's technology and the perceived valuation gaps with other peers in the NASH market as highlighted in Red Chips recent Analyst Report the release which instigated a strong rerating of the Company's share price. www.immuron.com/index.php/download_file/-/view/140/.

As previously announced, the Immuron Board see this as a critical stepping stone in the Company's US shareholder expansion and diversification plan as it pursues its application for a full listing on a US National Exchange in the coming months.

Contact:

Dr. Roger Aston
Chairman
Ph:+61 (0)3 9824 5254

Mr. Peter Anastasiou
Vice Chairman
Ph:+61 (0)419 511 604

ABOUT IMMURON

Immuron Ltd (ASX:IMC) is a Microbiom company focused on developing and commercialising oral immunotherapeutics for the treatment of a many gut mediated diseases. Immuron has a unique and safe technology platform that enables a shorter development therapeutic cycle. The company currently markets Travelan® for the prevention of travelers' diarrhea, its lead product candidate IMM-124E is in Phase 2 clinical trials for NASH and ASH, and it has a preclinical immunotherapy pipeline targeting immune-related diseases with unmet needs.

Immuron's main scientific alliances are with Hadassah Medical Center (Israel), Monash University (Australia) and the Commonwealth Scientific and Industrial Research Organisation (CSIRO) (Australia).